Gilead Sciences Inc.: Takeaways from our KOL call on GILD’s Yeztugo launch in HIV PrEP

Research evidence excerpt

Gilead Sciences Inc.: Takeaways from our KOL call on GILD’s Yeztugo launch in HIV PrEP

Accessible version

Gilead Sciences Inc.

Takeaways from our KOL call on GILD’s

Yeztugo launch in HIV PrEP

Maintain Rating: BUY | PO: 162.00 USD | Price: 129.90 USD

Yeztugo approval growing the HIV PrEP market 18 May 2026

We hosted Dr. Kassem Bourgi, infectious disease specialist, to discuss the evolving HIV Equity

PrEP treatment paradigm with a specific focus on early real-world experience with

Tazeen Ahmad

GILD’s Yeztugo. Our KOL highlighted an overall positive view on Yeztugo, noting it as a Research Analyst

highly differentiated therapy vs current options given its convenient dosing regimen, BofAS +1 646 855 4236

reduced patient and physician burden and favorable tolerability. Additionally, he cited tazeen.ahmad@bofa.com

benefits from existing infrastructure from Apretude. Early uptake has been driven Daniel Giraldo

primarily by patient-driven switches, particularly from Apretude, rather than PrEP-naïve ResearchBofAS Analyst

starts. Our KOL believes Yeztugo could expand the PrEP market through broader disease daniel.giraldoperez@bofa.com

and therapy awareness. He estimates that in about 12-18 months roughly half of his Jeremiah Lorentz

PrEP-eligible patients could be on Yeztugo, which we note is in-line with recent GILD ResearchBofAS Analyst

commentary on Yeztugo overtime becoming the leading PrEP therapy (see our 5/13 jeremiah.lorentz@bofa.com

Vegas dinner takeaways note). We maintain our Buy with $162 PO. Wesley Yon

Research Analyst

Strong initial persistence, likely to normalize BofASwesley.yon@bofa.com

He noted early Yeztugo retreatment rates are favorable with nearly all eligible patients

having been retreated or scheduled for retreatment with only one patient dropping off